Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that minoxidil increased 17ß-hydroxysteroid dehydrogenase activity by nearly 40% in dermal papilla cells from balding scalps but not in nonbalding scalp cells or dermal fibroblasts.

COVID-19 can cause or worsen skin conditions and might show early signs of infection.

In this study, a 9-year-old girl with female pattern hair loss showed clinical improvement and hair regrowth after six months of daily oral spironolactone.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

This study found that in female patients with COVID-19-related hair loss, diffuse hair loss and antinuclear antibody positivity might be linked to high antibody levels triggered by the infection.

This study found that 17α‐estradiol increases aromatase activity in female hair follicles, which may explain its beneficial effects in treating androgenetic alopecia.

This study found that topical application of hair lotion containing 17α-estradiol may reduce androgenetic hair loss, as 63% of treated patients showed a decrease in telogen hairs compared to 37% in the control group.

This study suggests that a 1,550-nm fractional erbium-glass laser may stimulate hair growth in both an alopecia mouse model and human subjects with male pattern hair loss, though further research is needed to determine its clinical applications.

This study examined 4-azasteroids using 13C-NMR spectroscopy, detailing the NMR spectrum assignments and reporting a new molecular complex of finasteride with dioxane.

This study found no significant association between selected gene variants and female pattern hair loss, suggesting these genes might not be involved in its development.

This study found that using anhydrous cerium(III) chloride with alkyl Grignard reagents significantly improved the addition to sterically hindered 17-ketosteroids, resulting in high yields and stereoselectivity.

This study found that men with androgenic alopecia had significantly higher levels of certain urinary steroid metabolites, suggesting increased 5 alpha-reductase activity and possible mild hyperadrenal activity.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This article reviews the use of various treatments for alopecia and their potential impact on COVID-19 outcomes, emphasizing the importance of patient registries in generating real-world evidence; it reports no new results.

This study identified three subgroups of women with PCOS with distinct androgen profiles, finding that the subgroup with adrenal-derived androgen excess had the highest insulin resistance and rates of hirsutism and hair loss.

This study reports that cutaneous manifestations such as herpes zoster, purpura, and livedo reticularis in COVID-19 patients can potentially indicate disease severity, aiding in the prediction of the illness's progression and guiding dermatological management during the pandemic.

This article discusses advances in hair transplantation techniques, particularly follicular unit extraction (FUE), emphasizing its advantage of avoiding donor site scarring and allowing for short hairstyles.

This study found that knocking down SFRP2 in an AGA model improved hair regeneration and reduced cellular dysfunction, suggesting that targeting the SFRP2-FSTL1 axis could be a promising therapeutic strategy for androgenetic alopecia.

This study found that patients with androgenetic alopecia had increased scalp microbial diversity and reduced Staphylococcus abundance, particularly in the frontal and vertex regions, suggesting this dysbiosis as a sensitive indicator of AGA.

In this study, researchers observed significant differences in hair follicle microbiome diversity and microbial composition between hair loss and healthy groups, uncovering specific patterns and functional changes associated with female pattern hair loss, which may aid future targeted approaches for androgenetic alopecia.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

In this pilot study, researchers found that fractional picosecond laser therapy may promote hair regrowth in men with mild-to-moderate androgenetic alopecia, with significant improvements in expert assessments and patient satisfaction observed over a four-month period, though further research is needed to confirm these findings.

In this study, researchers examined men with early-stage androgenetic alopecia and found distinct patterns of hair loss correlated with genetic and hormonal factors, noting that parietal region pattern hair loss responded better to minoxidil and micronutrient treatment compared to occipital region pattern.

This study suggests that Artemis, particularly phosphorylated at serine 516, may have roles in hair follicle growth by influencing differentiation, proliferation, apoptosis, and cell cycling.

This study found that VEGFR-2 activation may play a role in hair follicle differentiation, proliferation, and apoptosis by co-expressing with several key proteins in normal human scalp skin.

This study demonstrated that in genetic mouse models, the calcium sensor Stim1, not Stim2, is essential for sweat secretion in sweat glands.

This article compiles stem cell and regenerative medicine developments from industry press releases in September 2016, reporting no new study results.

This case report observed that a 23-year-old man developed painful unilateral gynecomastia after two months of low-dose finasteride treatment for male androgenetic alopecia, which resolved after discontinuation.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.